US-Chinese pharma dispute settles at ICC
Nerlynx
US and Chinese pharma companies have settled an ICC arbitration over the licensing of rights to promote a breast cancer drug in Greater China.
To read more
Subscribe to Global Arbitration Review
Subscribe and start reading now
Global Arbitration Review (GAR) is the online home for international arbitration specialists, telling them everything they need to know about all the developments that matter.
Subscribe now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10